EVOFEM BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Diluted
EVOFEM BIOSCIENCES, INC. (EVFM) reported Net Income (Loss) Available to Common Stockholders, Diluted of $2.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-15
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was $309.00K.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$2.00M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$8.48M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was $71.27M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $2.29M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was $52.68M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$78.01M.
- EVOFEM BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$206.24M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $2.29M 10-K · filed 2026-03-11 | ||||
| 2025-03-31 | $309.00K 10-Q · filed 2026-05-15 | $136.00K 10-Q · filed 2025-05-15 | |||
| 2024-06-30 | -$2.00M 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | -$8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $62.78M derived: sum of 2 quarters · filed 2025-03-24 | $52.68M 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $71.27M 10-Q · filed 2024-11-14 | $61.16M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | -$78.01M 10-K · filed 2023-04-27 | ||||
| 2022-09-30 | -$19.51M 10-Q · filed 2023-11-14 | -$143.58M derived: sum of 2 quarters · filed 2023-11-14 | -$175.55M derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$124.07M 10-Q · filed 2022-08-12 | -$156.04M 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | -$31.97M 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | -$206.24M 10-K · filed 2023-04-27 | ||||
| 2021-06-30 | -$33.43M 10-Q · filed 2022-08-12 | -$79.58M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$46.15M 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | -$142.31M 10-K · filed 2022-03-10 |